• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    Neuralstem, Inc. (CUR)

    0.34 Down 0.02(4.72%) May 27, 4:00PM EDT
    ProfileGet Profile for:
    Neuralstem, Inc.
    20271 Goldenrod Lane
    2nd Floor
    Germantown, MD 20876
    United States - Map
    Phone: 301-366-4841
    Website: http://www.neuralstem.com

    Index Membership:N/A
    Full Time Employees:32

    Business Summary 

    Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds. The company’s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical development products include NSI-189, which has completed Phase I clinical trial for the treatment of major depressive disorder, as well as is in Phase I clinical trial for the treatment of other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy; and NSI–566 that has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. The company was founded in 1996 and is headquartered in Germantown, Maryland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Neuralstem, Inc.

    Corporate Governance 
    Neuralstem, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 5; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Karl Y. Johe Ph.D., 56
    Co-Founder, Chairman and Chief Scientific Officer
    Mr. I. Richard Garr J.D., 63
    Co-Founder and Director
    Mr. Jonathan Brian Lloyd Jones ACA, MBA, 55
    Chief Financial Officer
    Mr. Richard J. Daly , 55
    Chief Exec. Officer, Pres and Director
    Dr. Thomas Hazel Ph.D.,
    Sr. VP of Research
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders